Emphasizing the importance of rigorous methodology, the Food and Drug Administration cautioned Thursday against drawing any hasty conclusions regarding the efficacy of several dozen fast-tracked products currently circulating in the bloodstreams of millions of Americans.
The agency noted that while the pharmaceutical treatments and surgically implanted hardware have been on the market for over half a decade, the clinical data remains highly preliminary. Regulators stressed that patients should avoid definitively assuming the medical products they rely on every day are strictly harmless until the manufacturers’ overdue postmarket safety studies are eventually initiated.
Pointing to a recent JAMA paper evaluating a widely distributed, expedited cardiac valve, researchers found that the manufacturer’s required safety follow-ups were running nearly 48 months behind schedule. Because the existing data relies primarily on self-reported survival rates, experts caution that any claims of the valve successfully pumping blood remain largely anecdotal and require further longitudinal observation before a consensus can be reached.
While an estimated 400,000 individuals currently have this hardware permanently fused to their arterial walls, the peer-reviewed literature is simply too sparse to confirm whether it belongs there.
The FDA further warned that forcefully pulling the unstudied devices from the market could introduce unforeseen confounding variables into the ongoing, permanently delayed clinical trials. Removing an unverified device, the agency noted, is a known risk factor for disrupting the natural cohort of patients who are currently serving as an uncontrolled, unconsenting control group for the wider medical industry.
To mitigate potential observational bias, the official guidance recommends that patients who experience a sudden, catastrophic device failure should remember that correlation does not necessarily equal causation. Citizens are advised to wait for a larger sample size of fatalities to be published in the literature before deciding to adjust their daily protocol.